Mekinist (Trametinib Dimethyl Sulfoxide) Patent Expiration, LOE Window & CMS Spending
Mekinist (Trametinib Dimethyl Sulfoxide) by Novartis: FDA Orange Book core substance LOE 2031-04-15 (last listed 2034-02-28), 0 AB generics, $275.6M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Novartis |
| FDA Application & Pathway | N204114 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2031-04-15 |
| Last Listed Patent or Exclusivity Date | 2034-02-28 |
| Orange Book Patents (*PED Extensions) | 16 patents (8 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $275.6M |
| 2024 Medicare Part D Spend | $207.0M |
| 2024 Medicaid Spend | $68.6M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 26.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.